Table 3 Remission rate after 1 year of follow-up treatment
Total | CR | PR | CR + PR |
|---|---|---|---|
MN(N = 180) | 63/180 (35.0%) | 79/180 (43.9%) | 142/180 (78.9%) |
FSGS-(N = 146) | 53/146 (36.3) | 67/146 (45.9) | 120/146 (82.2)* |
FSGS+(N = 34) | 10/34 (29.4) | 12/34 (35.3) | 22/34 (64.7) |
Pred + CTX | |||
FSGS-(N = 81) | 33/81 (40.7) | 31/81 (38.3) | 64/81 (79.0) |
FSGS+(N = 18) | 8/18 (44.4) | 6/18 (33.3) | 14/18 (77.7) |
Pred + CsA/ TAC | |||
FSGS-(N = 65) | 20/65 (30.8) | 36/65 (55.4) | 56/65 (86.2)** |
FSGS+(N = 16) | 2/16 (12.5) | 6/16 (37.5) | 8/16 (50.0) |
Pred + CsA | |||
FSGS-(N = 34) | 11/34 (32.3) | 16/34 (47.1) | 27/34 (79.4) |
FSGS+(N = 9) | 1/9 (11.1) | 4/9 (44.4) | 5/9 (55.5) |
Pred + TAC | |||
FSGS-(N = 31) | 9/31 (29.0) | 20/31 (64.5) | 29/31 (93.5)* |
FSGS+(N = 7) | 1/7 (14.3) | 2/7 (18.6) | 3/7 (42.8) |